Precision’s Wilder in PM360: Common Pitfalls to Avoid to Ensure a Successful Product Launch
After spending millions on R&D just to get a product to market—and millions more promoting it—there’s nothing worse than when a launch falls flat. In a just-published panorama on PM360, Precision for Value’s Kelly Wilder identifies several critical mistakes that pharma companies make that can reduce the perceived value of a product in the marketplace. (more…)
Precision’s Schafer in Drug Topics: The Future of Oncology Treatment Is Value Assessment
In this month’s Drug Topics, correspondent Kathleen Gannon Longo talks with Precision for Value’s Jeremy Schafer on the potentially tremendous impact that value assessments will have on future patient reimbursement decisions. (more…)
Maclean Talks Payer Access and New Opportunities Arising From Cures 3037
During the recent ISPOR conference, Ross Maclean, Precision Health Economics’ SVP, Head of Medical, sat down to talk with Med Ad News’ Christiane Truelove on new opportunities for payer access in light of new FDA draft guidance around section 3037 of the 21st Century Cures Act. (more…)
Precision’s Goldman and Lakdawalla in WSJ: Look to Major League Baseball for Drug Pricing Insight
In a new commentary appearing in The Wall Street Journal, Precision Health Economics cofounders Dana Goldman and Darius Lakdawalla turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. (more…)
Precision for Value’s Jackie DeAngelis Discusses Common Launch Mistakes
In a new commentary for PharmExec.com, Precision for Value SVP and Managing Director Jackie De Angelis outlines some of the most common mistakes that hinder access when launching a new drug. (more…)